

PBAC November 2020 Agenda Items

Lung Foundation Australia is seeking input from consumers to inform submissions on proposed listings of respiratory medicines on the Pharmaceutical Benefits Scheme (PBS).

We make submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) to support the timely listing of therapies that improve the health, social and economic outcomes of people impacted by lung disease or lung cancer. The perspectives and experiences of patients, carers, community members and health professionals are necessary to ensure decision makers understand the impact of life-changing and life-saving medicines on individuals, families and communities.

Individuals who have been on a trial for any of the following therapies, used the treatment or a similar treatment, or simply wish to support additional options for people impacted by lung diseases, are encouraged to contact Lung Foundation Australia to contribute to our submissions. Patients and their families may also make an individual submission to the PBAC.

Consumers wishing to contribute to Lung Foundation Australia's submissions should make contact by emailing patricias@lungfoundation.com.au by Friday 11 September with the following:

- One to two paragraphs on your personal experience of the therapy (how they used it and how it helped them and why an additional choice would be useful for you/your carers/and families)
- Your preferred contact number or email for an Lung Foundation Australia staff member to contact them and discuss further.

Drug name	Condition	Request
BEVACIZUMAB (Mvasi®)	Stage IV (metastatic) non-small cell lung cancer (NSCLC)	A request has been made to list a new biosimilar bevacizumab under the same conditions as the reference biologic.
DURVALUMAB (Imfinzi®)	Small cell lung cancer	A request has been made to list the treatment on the PBS in combination with etoposide and platinum-based chemotherapy for the first-line treatment of extensive stage SCLC.
NIVOLUMAB IPILIMUMAB (Opdivo®)	NSCLC	A request has been made to list the treatment on the PBS in combination with two cycles of chemotherapy for the first-line treatment of patients with Stage IV (metastatic) NSCLC.

BECLOMETASONE DIPROPIONATE + FORMOTEROL FUMARATE DIHYDRATE + GYLCOPYRRONIUM (Trimbow®)	Chronic Obstructive Pulmonary Disease (COPD)	A request has been made to list the treatment on the PBS for maintenance treatment of moderate to severe COPD.
DUPILUMAB (Dupixent®)	Asthma	A request has been made to list the treatment on the PBS for severe uncontrolled asthma.